A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection PEX168 Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection PEX168 Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs PEG loxenatide (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Jiangsu Hansoh Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 21 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top